Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis

BACKGROUND: This systematic review and meta-analysis included double-blind, randomized, placebo-controlled trials of brexpiprazole adjunctive treatment (0.5–3 mg/d) for major depressive disorder where antidepressant treatment had failed. METHODS: The outcomes were the response rate (primary), remiss...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishi, Taro, Sakuma, Kenji, Nomura, Ikuo, Matsuda, Yuki, Mishima, Kazuo, Iwata, Nakao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Regular Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872963/
https://www.ncbi.nlm.nih.gov/pubmed/31350882
http://dx.doi.org/10.1093/ijnp/pyz040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872963/
https://www.ncbi.nlm.nih.gov/pubmed/31350882
http://dx.doi.org/10.1093/ijnp/pyz040

Ejemplares similares